Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 21, 2011

A particle-enhanced turbidimetric immunoassay for quantitative determination of orosomucoid in urine: development, validation and reference values

  • Merete S. Christiansen , Søren Blirup-Jensen , Lise Foged , Marianne Larsen and Erik Magid


Increased urinary orosomucoid excretion rate (UOER) is an independent predictor of cardiovascular and all-cause mortality in patients with type 2 diabetes, as demonstrated by a conventional, immunoturbidimetric method. We wanted to optimize the method by developing a fully automated, particle-enhanced turbidimetric (PET) immunoassay with a lower detection limit, to allow assessment of orosomucoid in urine in healthy individuals and patients. A micro-particle-based immunoreagent was prepared for a PET immunoassay. The calibration was traceable to the certified reference material (CRM 470) for specific human serum proteins. We studied 69 healthy adults (28 men and 41 women) to establish reference values for the new assay. The detection limit of orosomucoid in urine was found to be 0.05 mg/l, about 20 times lower than for the conventional assay. Within-run imprecision [CV%, (level)] was 6.7% (0.23 mg/l), 1.0% (1.08 mg/l) and 1.0% (4.69 mg/l). Total imprecision [CV%, (level)] was 10.4% (0.23 mg/l), 3.9% (1.08 mg/l) and 3.4% (4.69 mg/l). Reference values [median (2.5–97.5 percentiles)] for UOER were 0.36 (0.07–2.04) µg/min and for urinary orosomucoid/creatinine ratio 0.04 (0.009–0.17) mg/mmol. We describe a fully automated, transferable, sufficiently precise, high-sensitivity assay for orosomucoid in urine and present reference values traceable to CRM 470.


1 Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44:1303–9.10.2337/diab.44.11.1303Search in Google Scholar

2 Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetics. Diabet Med 1984; 1:17–9.10.1111/j.1464-5491.1984.tb01915.xSearch in Google Scholar

3 Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356–60.10.1056/NEJM198402093100605Search in Google Scholar

4 Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16:996–1003.10.2337/diacare.16.7.996Search in Google Scholar

5 Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 1988; 5:126–34.10.1111/j.1464-5491.1988.tb00958.xSearch in Google Scholar

6 Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346:1080–4.10.1016/S0140-6736(95)91747-0Search in Google Scholar

7 Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. Nephropathy in diabetes. Diabetes Care 2004; 27Suppl 1:S79–S83.10.2337/diacare.27.2007.S79Search in Google Scholar PubMed

8 Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with type II diabetes. Diabetologia 2002; 45:115–20.10.1007/s125-002-8251-3Search in Google Scholar PubMed

9 Poortmans JR, Haralambie G. Biochemical changes in a 100 km run: proteins in serum and urine. Eur J Appl Physiol Occup Physiol 1979; 40:245–54.10.1007/BF00421516Search in Google Scholar PubMed

10 Tencer J, Thysell H, Grubb A. Analysis of proteinuria: reference limits for urine excretion of albumin, protein HC, immunoglobulin G, kappa- and lambda-immunoreactivity, orosomucoid and alpha 1-antitrypsin. Scand J Clin Lab Invest 1996; 56:691–700.10.3109/00365519609088816Search in Google Scholar PubMed

11 Ito S, Tsuda A, Momotsu T, Igarashi K, Kasahara S, Satoh K, et al. Urinary orosomucoid excretion rate in patients with non-insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1989; 120:584–90.10.1530/acta.0.1200584Search in Google Scholar

12 Vittinghus E. Preanalytical handling of stored urine samples, and measurement of beta 2-microglobulin, orosomucoid, albumin, transferrin and immunoglobulin G in urine by enzyme-linked immunosorbent assays (ELISA). Scand J Clin Lab Invest 1990; 50:843–9.10.3109/00365519009104951Search in Google Scholar

13 Blirup-Jensen S. Protein standardization III: method optimization. Basic principles for quantitative determination of human serum proteins on automated instruments based on turbidimetry or nephelometry. Clin Chem Lab Med 2001; 39:1098–109.10.1515/CCLM.2001.175Search in Google Scholar

14 Newman DJ, Henneberry H, Price CP. Particle enhanced light scattering immunoassay. Ann Clin Biochem 1992; 29(Pt 1):22–42.10.1177/000456329202900104Search in Google Scholar

15 Price CP, Spencer K, Whicher J. Light-scattering immunoassay of specific proteins: a review. Ann Clin Biochem 1983; 20(Pt 1):1–14.10.1177/000456328302000101Search in Google Scholar

16 Blirup-Jensen S. Protein standardization I: protein purification procedure for the purification of human prealbumin, orosomucoid and transferrin as primary protein preparations. Clin Chem Lab Med 2001; 39:1076–89.10.1515/CCLM.2001.173Search in Google Scholar

17 Weeke B. Crossed immunoelectrophoresis. In: Axelsen NH, Kroll J, Weeke B, editors. A manual of quantitative immunoelectrophoresis. Methods and applications. Oxford: Blackwell Scientific Publications,1973:47–56.Search in Google Scholar

18 Baudner S, Bienvenu J, Blirup-Jensen S, Carlström A, Johnson AM, Milford-Ward A, et al. The certification of a matrix reference material for immunochemical measurement of 14 human serum proteins CRM 470. EUR 15243 EN ed. Community Bureau of Reference, Commission of the European Communities, 1993:1–186.Search in Google Scholar

19 Blirup-Jensen S, Johnson AM, Larsen M. Protein standardization IV: value transfer procedure for the assignment of serum protein values from a reference preparation to a target material. Clin Chem Lab Med 2001; 39:1110–22.10.1515/CCLM.2001.176Search in Google Scholar

20 Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994; 40:934–8.10.1093/clinchem/40.6.934Search in Google Scholar

21 NCCLS Approved Guideline EP9-A. Method comparison and bias estimation using patient samples. Wayne, PA: National Committee for Clinical Laboratory Standards, 1995;15.Search in Google Scholar

22 NCCLS Approved Guideline EP5-A. Evaluation of precision performance of clinical chemistry devices. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999;19.Search in Google Scholar

23 NCCLS Proposed Guideline EP6-P. Evaluation of the linearity of quantitative analytical methods. Wayne, PA: National Committee for Clinical Laboratory Standards, 1986;18.Search in Google Scholar

24 NCCLS Approved Guideline EP15-A. User demonstration of performance for precision and accuracy. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000;18.Search in Google Scholar

25 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307–10.Search in Google Scholar

26 Dybkaer R, Solberg HE. International Federation of Clinical Chemistry (IFCC). Approved recommendation (1987) on the theory of reference values. Part 6. Presentation of observed values related to reference values. Clin Chim Acta 1987; 170:S33–S42.Search in Google Scholar

27 Solberg HE. International Federation of Clinical Chemistry (IFCC). Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. Clin Chim Acta 1987; 170:S13–S32.10.1016/0009-8981(87)90151-3Search in Google Scholar

28 Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916; 17:863–71.10.1001/archinte.1916.00080130010002Search in Google Scholar

29 Schmid K. Human plasma alpha 1-acid glycoprotein – biochemical properties, the amino acid sequence and the structure of the carbohydrate moiety, variants and polymorphism. Prog Clin Biol Res 1989; 300:7–22.Search in Google Scholar

30 Lögdberg L, Wester L. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. Biochim Biophys Acta 2000; 1482:284–97.10.1016/S0167-4838(00)00164-3Search in Google Scholar

31 Jensen H, Henriksen K. Proteinuria in non-renal infectious diseases. Acta Med Scand 1974; 196:75–82.10.1111/j.0954-6820.1974.tb00971.xSearch in Google Scholar PubMed

32 Pang JX, Ginanni N, Dongre AR, Hefta SA, Opitek GJ. Biomarker discovery in urine by proteomics. J Proteome Res 2002; 1:161–9.10.1021/pr015518wSearch in Google Scholar PubMed

33 Nielsen SH, Petersen JS, Magid E. Albuminuria in ischemic heart disease. Scand J Clin Lab Invest Suppl 1999; 230:143–52.10.1080/00365519909168338Search in Google Scholar

34 Tencer J, Thysell H, Andersson K, Grubb A. Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain-immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at –20 degrees C. Scand J Urol Nephrol 1997; 31:67–71.10.3109/00365599709070305Search in Google Scholar PubMed

35 Hemmingsen L, Skaarup P. The 24-hour excretion of plasma proteins in the urine of apparently healthy subjects. Scand J Clin Lab Invest 1975; 35:347–53.10.3109/00365517509095751Search in Google Scholar

36 Kordonouri O, Jorres A, Muller C, Enders I, Gahl GM, Weber B. Quantitative assessment of urinary protein and enzyme excretion – a diagnostic programme for the detection of renal involvement in type I diabetes mellitus. Scand J Clin Lab Invest 1992; 52:781–90.10.3109/00365519209088381Search in Google Scholar PubMed

37 Khalaf AN, Bocker J, Kerp L, Petersen KG. Urine screening in outdoor volunteers: day versus night versus 24 hour collection. Eur J Clin Chem Clin Biochem 1991; 29:185–8.10.1515/cclm.1991.29.3.185Search in Google Scholar PubMed

38 Cohen DL, Close CF, Viberti GC. The variability of overnight urinary albumin excretion in insulin-dependent diabetic and normal subjects. Diabet Med 1987; 4:437–40.10.1111/j.1464-5491.1987.tb00905.xSearch in Google Scholar PubMed

39 Howey JE, Browning MC, Fraser CG. Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. Clin Chem 1987; 33:2034–8.10.1093/clinchem/33.11.2034Search in Google Scholar

40 Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499–511.10.1161/01.CIR.0000052939.59093.45Search in Google Scholar

41 Johnsson E, Haraldsson B. Addition of purified orosomucoid preserves the glomerular permeability for albumin in isolated perfused rat kidneys. Acta Physiol Scand 1993; 147:1–8.10.1111/j.1748-1716.1993.tb09466.xSearch in Google Scholar

42 Sörensson J, Matejka GL, Ohlson M, Haraldsson B. Human endothelial cells produce orosomucoid, an important component of the capillary barrier. Am J Physiol 1999; 276:H530–H534.10.1152/ajpheart.1999.276.2.H530Search in Google Scholar

43 Sörensson J, Ohlson M, Björnson A, Haraldsson B. Orosomucoid has a cAMP-dependent effect on human endothelial cells and inhibits the action of histamine. Am J Physiol Heart Circ Physiol 2000; 278:H1725–H1731.10.1152/ajpheart.2000.278.5.H1725Search in Google Scholar

44 Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 2003; 14:25–34.10.1016/S1359-6101(02)00054-0Search in Google Scholar

45 Daemen MA, Heemskerk VH, van’t Veer C, Denecker G, Wolfs TG, Vandenabeele P, et al. Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation 2000; 102:1420–6.10.1161/01.CIR.102.12.1420Search in Google Scholar

46 Hochepied T, Van Molle W, Berger FG, Baumann H, Libert C. Involvement of the acute phase protein alpha 1-acid glycoprotein in nonspecific resistance to a lethal gram-negative infection. J Biol Chem 2000; 275:14903–9.10.1074/jbc.275.20.14903Search in Google Scholar PubMed

47 Muchitsch EM, Teschner W, Linnau Y, Pichler L. In vivo effect of alpha 1-acid glycoprotein on experimentally enhanced capillary permeability in guinea-pig skin. Arch Int Pharmacodyn Ther 1996; 331:313–21.Search in Google Scholar

48 Muchitsch EM, Auer W, Pichler L. Effects of alpha 1-acid glycoprotein in different rodent models of shock. Fundam Clin Pharmacol 1998; 12:173–81.10.1111/j.1472-8206.1998.tb00938.xSearch in Google Scholar PubMed

Received: 2004-6-11
Accepted: 2004-7-12
Published Online: 2011-9-21
Published in Print: 2004-10-1

© Walter de Gruyter

Downloaded on 7.6.2023 from
Scroll to top button